Nick Blondin

Exploring CNS tumors, they discuss incidence rates, challenges in treatment, and mortality. From meningiomas to gliomas, they cover radiological and pathological features, IDH mutations, and targeted therapies. They delve into grade two CNS tumors, MGMT gene impact on treatment outcomes, temozolomide toxicities, and treatment options for glioblastoma. Imaging characteristics of various CNS tumors are also explored.